Last reviewed · How we verify
Immunonutrition
Immunonutrition is a Small molecule drug developed by Centre Hospitalier Universitaire Vaudois. It is currently in Phase 3 development.
Immunonutrition is a dietary intervention that has been studied in clinical trials for its potential to improve the efficacy of immunotherapy in patients with metastatic non-small cell lung cancer. Clinical trials have investigated the effects of immunonutrition on patients with lung cancer, as well as on individuals with poor nutrition and immunological status.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Immunonutrition |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Vaudois |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study (NA)
- Critical Food Ingredients on Immunocompetence to Prevent the Risk and Development of Obesity/Metabolic Syndrome (NA)
- Pre-Surgical Immunonutrition's Effect on Colorectal Surgery (NA)
- Prehab for Pancreatic Cancer Surgery (NA)
- Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease (NA)
- Esophageal Cancer Multimodal Prehabilitation Study (NA)
- Phase II Trial of Immunonutrition in Hepatectomy (NA)
- Impact of Various Diets on Surgical Complications (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunonutrition CI brief — competitive landscape report
- Immunonutrition updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Vaudois portfolio CI
Frequently asked questions about Immunonutrition
What is Immunonutrition?
Who makes Immunonutrition?
What development phase is Immunonutrition in?
Related
- Manufacturer: Centre Hospitalier Universitaire Vaudois — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing